In a multicenter cohort of advanced lung adenocarcinoma patients treated with PD-(L)1 blockade, those with concurrent STK11 and KEAP1 mutations had lower objective response rates and shorter PFS and overall survival compared to patients with wild-type or single-mutant tumours [74]. This evidence concerns the gene STK11 and neoplasm.